ClearPoint Neuro (NASDAQ:CLPT) & Hyperfine (NASDAQ:HYPR) Head to Head Analysis

ClearPoint Neuro (NASDAQ:CLPT) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares ClearPoint Neuro and Hyperfine”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97 million	9.98	-$25.54 million	($0.91)	-13.53
Hyperfine	$11.40 million	15.04	-$35.57 million	($0.44)	-3.98

ClearPoint Neuro has higher revenue and earnings than Hyperfine. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ClearPoint Neuro and Hyperfine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-69.08%	-122.17%	-40.69%
Hyperfine	-262.29%	-95.09%	-71.11%

Institutional and Insider Ownership

30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by insiders. Comparatively, 26.3% of Hyperfine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

ClearPoint Neuro has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for ClearPoint Neuro and Hyperfine, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1	0	2	0	2.33
Hyperfine	1	2	3	0	2.33

ClearPoint Neuro currently has a consensus price target of $18.00, suggesting a potential upside of 46.22%. Hyperfine has a consensus price target of $1.59, suggesting a potential downside of 9.29%. Given ClearPoint Neuro’s higher possible upside, equities research analysts plainly believe ClearPoint Neuro is more favorable than Hyperfine.

Summary

Hyperfine beats ClearPoint Neuro on 7 of the 13 factors compared between the two stocks.

About ClearPoint Neuro

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

About Hyperfine

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.